Chronic kidney disease (CKD) is now a recognized global public health problem. It is highly prevalent and strongly associated with hypertension and cardiovascular disease (CVD); far more patients with a glomerular filtration rate below 60 ml min À1 per 1.73 m 2 will die from cardiovascular causes than progress to end-stage renal disease. A better understanding of the complex mechanisms underlying the development of CVD among CKD patients is required if we are to begin devising therapy to prevent or reverse this process. Observational studies of CVD in CKD are difficult to interpret because renal impairment is almost always accompanied by confounding factors. These include the underlying disease process itself (for example, diabetes mellitus and systemic vasculitis) and the complications of CKD, such as hypertension, anaemia and inflammation. Kidney donors provide an ideal opportunity to study healthy subjects without manifest vascular disease who experience an acute change from having normal to modestly impaired renal function at the time of uninephrectomy. Prospectively examining the cardiovascular consequences of uninephrectomy using donors as a model of CKD may provide useful insight into the pathophysiology of CVD in CKD and, therefore, into how the CVD risk associated with renal impairment might eventually be reduced.
Introduction
Chronic kidney disease (CKD) is a major but poorly recognized and undertreated risk factor for cardiovascular disease (CVD). 1 It is divided into five stages predominantly according to glomerular filtration rate (GFR), which can be measured accurately using radionuclide techniques 2 or estimated using formulae such as the Modification of Diet in Renal Disease (MDRD) equation (Table 1) . 3 Data from the National Health and Nutrition Examination Survey (NHANES) shows that the prevalence of CKD is both high and rising; over 13% of US citizens fulfil National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF K/DOQI) criteria for stage 1-4 CKD. 4 Although this figure excludes patients with end-stage renal disease, a population associated with extreme cardiovascular risk, in public health terms, the principal CVD burden resides in early-stage CKD, which is over 50 times more prevalent ( Figure 1 ). 5 Numerous observational studies have demonstrated the excess cardiovascular risk associated with CKD. [6] [7] [8] [9] [10] [11] [12] In a study of over a million US adults in whom serum creatinine was measured between 1996 and 2000, there was an independent, graded inverse relationship between estimated GFR (eGFR) at levels below 60 ml min À1 per 1.73 m 2 and the risk of adverse cardiovascular events. 7 Although there is a consensus from international organizations (NKF K/DOQI 3 and Kidney Disease: Improving Global Outcomes 13 ) that individuals with a GFR of o60 ml min À1 per 1.73 m 2 are at increased risk of cardiovascular morbidity and mortality, and that the risk increases with decreasing GFR, this 'threshold' value is still subject to question. Many studies have simply used subjects with an eGFR of 460 ml min À1 per 1.73 m 2 as their reference population when considering cardiovascular risk. A recent metaanalysis of 1 234 182 participants taken from general population cohorts found that all-cause and cardiovascular mortality began rising at an eGFR o75 ml min À1 per 1.73 m 2 . 10 The Belgian Inter-University Research on Nutrition and Health Population Study followed 8913 apparently healthy participants for a total of 10 years. 11 Interestingly, the results suggested that excess cardiovascular mortality began even earlier at an eGFR o90 ml min À1 per 1.73 m 2 , a level commonly regarded as indicating near-normal renal function. The cardiovascular mortality risk increased linearly by 8% for every 10 ml min À1 per 1.73 m 2 fall in eGFR. This is a potentially very important finding given the high prevalence of eGFR values in this range, particularly in the elderly in whom the loss of renal function has hitherto been regarded as benign.
Several studies have also shown a graded relationship with cardiovascular risk and the level of albuminuria. 10, 14, 15 In the general population, even low levels of urinary albumin excretion, below the current diagnostic threshold for microalbuminuria, have been shown to predict future CVD including death independent of other 'traditional' cardiac risk factors. 14, 15 This finding was recently confirmed by a CKD Prognosis Consortium meta-analysis where albumin:creatinine ratio (ACR) was independently associated with adjusted risk of all-cause and cardiovascular mortality with a log-linear relationship, but there was no evidence of the threshold effect that has been postulated for GFR. 10 Indeed, the hazard ratio for all-cause and cardiovascular mortality is already doubled within the ACR range of 0.3-3.0 mg mmol À1 , a level that is not detected by standard urinary dipsticks and has often been considered innocuous. Furthermore, the risks of all-cause and cardiovascular mortality appear to be independently and multiplicatively associated with eGFR and albuminuria. 10 Proteinuria is also associated with the progression of renal disease 16 and may even have a causal role through toxicity to tubular epithelial cells. 17 Enticingly, albuminuria could be more than just a passive biomarker of CVD. The PREVEND Group has shown that treating normotensive microalbuminuric individuals with an angiotensin-converting enzyme inhibitor resulted in a significant reduction in urinary albumin excretion and was also associated with a trend in reducing cardiovascular events compared with placebo. 18 The strong and consistent evidence for excess cardiovascular risk in CKD suggests but does not confirm a causal relationship. Cross-sectional studies of CKD are almost invariably confounded by factors such as the underlying disease (for example, hypertension, diabetes mellitus and systemic vasculitis) and the sequelae of CKD, including hypertension, anaemia and inflammation. Thus, it remains possible that renal disease itself does not cause CVD but represents a clustering of cardiovascular risk factors. A prospective longitudinal study of subjects who develop a decline in GFR and/or albuminuria is required to examine the effects of new-onset renal dysfunction on the cardiovascular system. In human studies, this is difficult because the duration of kidney disease is seldom evident at the time of presentation. Kidney donors, however, provide a near-ideal experimental model, as they are a healthy population, screened to exclude confounding comorbidity, in whom renal function declines suddenly at a known time point.
Current status of living donor kidney transplantation
Renal transplantation is the optimal treatment for the majority of patients with end-stage renal disease, but demand exceeds the supply of cadaveric organs. Over the last decade, there has been substantial growth in the practice of living kidney donation. In the UK alone, 1037 live donor transplants were performed in 2009, reflecting an annual increase of 15% (Table 2) . 19 This increased activity has been replicated worldwide and can be attributed to a number of factors, including improved patient education, 20 recognition of its cost effectiveness, 21, 22 use of minimally invasive laparoscopic nephrectomy reducing donor morbidity, 23 evidence that preemptive transplants performed from living kidney donors have better graft survival than those from Effects of chronic kidney disease on cardiovascular risk WE Moody et al cadaveric donors 24 and the acceptance that outcomes from living genetically unrelated donors are equivalent to traditional genetically related donations. 25 Over the last decade, the number of live kidney donor nephrectomies performed in the US and Canada has doubled and now accounts for over 40% of all kidney transplants. 26 Similarly, in the UK, living kidney donors now comprise 38% of the total kidney transplant programme. 19 The criteria for 'fitness' to undergo donor nephrectomy were initially very strict in an attempt to minimize both operative and long-term risks in subjects undergoing surgery for no physical benefit. Subjects were intensively screened before surgery so that kidney donors comprised a super-fit population, with lower levels of comorbidity and CVD risk than the general population. Recently, however, with an ever-growing waiting list for kidney transplantation, exclusion criteria for living donors have become more relaxed. Centres are now accepting subjects with a lower GFR than may have been considered appropriate in the past, as well as older age groups, those with controlled hypertension and those with raised body mass index. 26, 27 The potential long-term renal and cardiovascular risks of kidney donation may be most relevant to these 'expanded-criteria' donors.
Renal function after kidney donation
Glomerular filtration rate Uninephrectomy is associated with an acute 50% reduction in GFR, followed by an improvement to about 70% of baseline within weeks secondary to glomerular hypertrophy and hyperfiltration in the remaining kidney. 28, 29 Long-term longitudinal studies comparing early and late post-donation GFR have found no evidence of a further decline in mean function over periods of between 10 and 30 years. 30 In a meta-analysis of 48 cross-sectional studies involving over 3000 donors and 1703 controls, uninephrectomy was associated with a reduction in GFR of 17.1 ml min À1 per 1.73 m 2 (95% CI À20.2 to À14.0 ml min À1 per 1.73 m 2 ) that tended to improve slightly with each 10 years of follow-up. 31 These findings are difficult to interpret as GFR was measured by a variety of methods, including creatinine clearance by timed collection and estimated values derived from serum creatinine concentration, both of which are known to be inaccurate particularly at the modestly subnormal GFR levels expected after donation. [32] [33] [34] Ibrahim et al. 35 measured GFR by iohexol clearance in a randomly selected sample of 255 donors at a mean of 12 years after donation and found a mean GFR of 63.7±11.9 ml min À1 per 1.73 m 2 , 76% of the estimated level at the time of donation. Fifteen percent of donors fulfilled criteria for stage 3 CKD, although in no case was the value o30 ml min À1 per 1.73 m 2 . In a recent study using 125 I-iothalamate GFR, a more accurate assessment of renal function, the overall prevalence of stage 3 CKD in 196 donors at 3 months after nephrectomy was higher at 27%; this proportion was heavily age dependent, however, with only 10% of donors under 30 years of age falling into this category compared with 91% of those aged 60-69 years. 32 The figures for stage 3 CKD according to eGFR are even higher (Figure 2 ), and it is worth remembering that the graded association between CKD and cardiovascular risk emerged from observational studies that used eGFR as their index of renal function. These data are supported by our own analysis of 71 donors transplanted in 2009 at Queen Elizabeth Hospital, Birmingham, UK. Despite a mean baseline isotopic GFR (iGFR) of 100 ml min À1 per 1.73 m 2 using 51 Cr-EDTA clearance and a mean donor age of only 47 years, 65% had an eGFR o60 ml min À1 per 1.73 m 2 at 3-12 months after nephrectomy (unpublished data, Figure 3) .
The risk of developing CKD of any category after donation is dependent upon race and age. In a large US study of health outcomes after kidney donation, older age at donation was associated with an increased risk of 4% per year of age of 'medically coded' CKD. 36 Black and Hispanic donors were approximately twice as likely to develop CKD after nephrectomy as white donors. Of more concern was the finding that black donors were at increased risk of progressing to end-stage renal disease over 20 years, with an incidence of nearly 1% (2 out of 271) Effects of chronic kidney disease on cardiovascular risk WE Moody et al compared with o0.5% in Hispanics and 0% in whites.
Proteinuria
A number of studies have demonstrated an increase in protein excretion following kidney donation. In a meta-analysis of 48 studies involving 5048 donors, at an average of 7 years after donation, the average 24-h urinary protein excretion was 154 mg per day (above the upper limit of normal protein excretion, see Table 3 ). 31, 37 The pooled incidence of clinical proteinuria (4300 mg per day) was 12%, and compared with controls, the pooled risk of microalbuminuria was increased at 3.9 (relative risk 3.9, 95% CI 1.2-12.6). The effect of normal ageing was investigated by analyzing three studies involving 129 donors and 59 controls. At an average of 11 years after donation, 24-h urinary protein was higher in donors compared with controls (147 versus 83 mg per day). This difference increased with time from donation, suggesting a progressive effect. Higher levels of proteinuria are seen in donors with hypertension, [38] [39] [40] and males are at greater risk than females. 41 More recently, Ibrahim et al. 35 reported that in 255 donors selected randomly from 3698 nephrectomies performed at the University of Minnesota between 1963 and 2007, 11.5% had microalbuminuria, whereas 1.2% had macroalbuminuria at a mean of 12.2 years after donation. There was a log-linear increase in albumin:creatinine ratio with time following donation, although as there was no control group, it is not possible to distinguish this from the effect of ageing.
Risk of hypertension after kidney donation
A meta-analysis of 48 mainly retrospective studies from 28 countries examined blood pressure (BP) changes following kidney donation in 5145 donors. 42 Of these, only 10 studies used a control group of similar age, sex and ethnicity. Most failed to find a statistically significant change in BP but were almost certainly underpowered. The pooled estimates, however, did show that compared with controls, systolic BP increased by 5 mm Hg and diastolic BP by 4 mm Hg at B10 years after donation. The Norwegian Living Donor Registry of 256 donors at 5 years after nephrectomy also demonstrated an increase in systolic BP of about 5 mm Hg and an increased prevalence of hypertension at 27% compared with 3% before donation. 43 A retrospective cohort study of 1278 donors showed an increase in diagnosed hypertension compared with controls at a mean of 6.2 years (16.3 versus 11.9%, hazard ratio 1.4, 95% CI 1.2-1.7). The same study also noted that donors were seen more often by their primary care physicians, raising the possibility that the increased prevalence might have been due to increased monitoring. 44 In the University of Minnesota Study, mean 'office' systolic BP in the 255 patients following nephrectomy was 122 mm Hg, significantly lower than an age-matched control population. 35 The prevalence of hypertension requiring drug therapy was 25%, not significantly different from the figure of 29% in the control population. A longitudinal study over 10 years did show an increased prevalence of hypertension in donors when compared with age/sex-matched data from epidemiological studies of the general population (both in the UK and the US). 30 The prevalence of hypertension was 36% at an initial visit 1-21 years after donation, increasing to 75% after 10 years. This effect was especially strong in those donating over the age of 55 years. It appears that baseline BP influences the magnitude 45, 46 Older age at donation is also associated with an increased risk of postdonation hypertension, with an effect size of 6% per year. 36 The well-recognized racial disparities that affect the development and progression of hypertension in the general population are also apparent among living kidney donors. In a large retrospective study of 4650 donors, the prevalence of hypertension at 5 years from donation varied from 13.9% in young white women to 47.9% in black men over 50 years of age. 36 At a median of 7 years, the risk of hypertension in black and Hispanic donors was greater than that of white donors, with an adjusted hazard ratio of 1.52. The risk of hypertension in Hispanics exceeded control values from NHANES data, and there was a similar trend in black donors that could not be accounted for by socioeconomic factors. These data are further supported by a study demonstrating hypertension in as many as 41% of black donors at a mean follow-up of 7 years after nephrectomy. 47 In a single centre retrospective cohort study, hypertension was diagnosed more frequently among 38 indigenous North American donors compared with 76 randomly selected white donor controls (NA 42% versus white 19%, P ¼ 0.02). 48 
Risk of diabetes mellitus after kidney donation
Animal work has suggested that kidney donation might be associated with an increased risk of type 2 diabetes mellitus (T2DM). Sprague-Dawley rats develop glucose intolerance and islet b-cell loss 8 months after uninephrectomy. 49, 50 To date, there is no evidence to confirm an increased risk of developing T2DM in humans following kidney donation. No effect on insulin resistance was detected in an uncontrolled observational cohort study of 58 living donors at 6 months after donation. 51 In a retrospective survey of 3777 kidney donors at a mean of 18 years after donation, 154 of the 2954 respondents (6%) had developed T2DM. 52 This proportion is roughly equivalent to that observed in the general population, suggesting it probably represents an effect of ageing, but the lack of control group might have concealed an excess risk associated with donation. Those who did develop T2DM were more likely to have hypertension (70.8 versus 36.2%, P ¼ 0.005) and proteinuria (18.8 versus 3.9%, Po0.0001) but had a similar eGFR when compared with matched controls. Risk factors associated with an increased risk of developing T2DM included male gender and body mass index 430 kg m À2 at the time of donation. Black, Hispanic 52 and native North American donors 48 also appear to be at increased risk of developing T2DM following nephrectomy compared with white donors.
Other cardiovascular consequences of kidney donation
Two cross-sectional studies have examined arterial stiffness in kidney donors, 53,54 a well-validated measure of arterial function that is independently predictive of cardiovascular mortality in a range of populations, including hypertension and CKD. 55 Increased arterial stiffness in CKD is thought to have a central role in promoting the adverse changes in cardiac structure and function, which predispose to an increased risk of cardiovascular death. Its mechanistic importance has recently been reviewed (Figure 4) . 56 Aortic pulse wave velocity, the current gold-standard marker of arterial stiffness, was found to be significantly higher in 101 donors at a mean of 111 ± 42 months after nephrectomy relative to a healthy volunteer group, even after adjustment for age, sex and BP. 53 The second study of 40 living kidney donors included echocardiographic assessment at an average of 7 years after nephrectomy. 54 When compared with controls, donation was associated with increased pulse wave velocity, as well as increased left ventricular relative wall thickness and left atrial size.
Survival and health status after kidney donation
The results of existing long-term follow-up studies suggest that far from suffering an increased risk of early mortality, kidney donors have an excellent prognosis. Indeed, a widely quoted Swedish study Figure 4 Mechanistic pathway showing consequences of increased arterial stiffness in CKD. Increased arterial stiffness leads to increases in systolic BP and pulse pressure causing myocyte hypertrophy, increased ventricular afterload and reduced coronary perfusion, resulting in diastolic and systolic dysfunction and ultimately congestive heart failure. Raised systolic and pulse pressures also promote further vascular damage, increasing the risk of stroke and further loss of kidney function. Reproduced with permission from Chue et al. 56 that followed the health status of 430 kidney donors between 1964 and 1994 suggested that donors tend to live longer than the general population. 57 These results have just been confirmed in a registry study of over 80 000 US donors between 1994 and 2009, with a median follow-up period of over 6 years in which the mortality of live kidney donors was slightly lower than that of matched controls from the NHANES III cohort. 58 Similarly, Ibrahim et al. 35 found no significant difference in survival between 3698 donors who donated kidneys between 1963 and 2007 and a NHANES cohort matched for age, sex and race. Quality of life was better than population norms, and coexistent health problems were not significantly different. This lack of excess morbidity and mortality among kidney donors represents a paradox in the face of the strong evidence from epidemiological studies that show a clear and graded association between reduced GFR and cardiovascular risk. It may be explained by residual confounding related to the difficulty in identifying an equivalent control group to kidney donors. Before transplantation, these individuals undergo intensive health screening, and because the finding of almost all disease states (apart from mild hypertension) leads to exclusion from donation, they are not representative of the general population. Indeed, based on accepted living kidney donor exclusion criteria, 16 more than half of the NHANES cohort would have been found to be ineligible for live donation. 35, 58 Donors are well motivated, often making substantial healthy lifestyle modifications both before and after surgery, which may lead to further confounding. It is also worth highlighting that thus far, with the exception of the recent report by Segev et al., 58 virtually all studies of kidney donors are retrospective with low inclusion rates making them heavily subject to selection bias. It remains possible, however, that the cross-sectional studies relating reduced eGFR to CVD are incorrect, perhaps because of residual confounding by disease states that tend to coexist with CKD that have not been adequately corrected for by the investigators. Lastly, as age is a factor in the calculation of eGFR using the MDRD formula, these two entities are inextricably linked. It is possible, therefore, that the epidemiological association of CKD with CVD is, at least in part, an effect of age rather than true GFR. 59 
Future studies
There is now a clear requirement for prospective registration of all living kidney donors. This will provide much needed quality data on the long-term health consequences of living kidney donation and protect its widespread practice by improving the available information for potential donors. Even with such information, however, unless highly screened healthy control groups are also recruited for comparison, it will be impossible to truly determine whether kidney donation impacts adversely upon cardiovascular risk.
A potentially fruitful line of investigation might be to examine the impact of uninephrectomy for kidney donation on prognostically important functional and structural cardiovascular variables, such as arterial stiffness, BP, left ventricular mass and endothelial function. Detailed pathophysiological studies employing accurate, direct measures of GFR would allow quantification of the level of reduced renal function at which excess cardiovascular risk begins and also distinguish the effects of reduced renal function from those of aging. If adverse effects on these well-recognized surrogate markers were detected, it would inform clinical decisions on whether cardiovascular risk reduction therapy should be instituted in patients with early-stage CKD, a significant proportion of the western population, as well as in all living kidney donors. Studying kidney donors can help to inform the debate on whether targeting renal disease itself has the potential to reduce cardiovascular risk. We suggest that, henceforth, donors should be invited to participate prospectively in both pathophysiological and epidemiological studies, as current information on this valuable cohort is inadequate. In the meantime, there is no reason to limit the expansion in living donor kidney transplantation; the risk of premature mortality in the donor is low, and the gain in quality and quantity of life for the recipient is high so that the composite benefit to the community is clear.
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